Symptoms: decreased BLOOD pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment: симптоматическое.
Preparation MILDRONATE® is low-toxic and does not cause adverse reactions dangerous to the health of patients.
Symptoms: decreased BLOOD pressure, accompanied by headache, tachycardia, dizziness and general weakness.
Treatment: симптоматическое.
Preparation 3- (2,2,2-Trimethylhydrazinium® is low-toxic and does not cause adverse reactions dangerous to the health of patients.
hypersensitivity to the components of the drug
increased HDV (with violation of venous outflow, intracranial tumors)
pregnancy
period of breastfeeding
age up to 18 years (efficacy and safety not established).
With caution: заболевания печени и/или почек.
Can be combined with antianginal drugs, anticoagulants, antiplatelet drugs, antiarrhythmics, diuretics, bronchodilators.
Enhances the effect of cardiac glycosides.
In view of the possible development of moderate tachycardia and arterial hypotension, care should be taken in combination with nitroglycerin, nifedipine, alpha-blockers, other hypotensive agents and peripheral vasodilators, since the drug MILDRONATE® enhances their action.
Can be combined with antianginal drugs, anticoagulants, antiplatelet drugs, antiarrhythmics, diuretics, bronchodilators.
Enhances the effect of cardiac glycosides.
In view of the possible development of moderate tachycardia and arterial hypotension, care should be taken in combination with nitroglycerin, nifedipine, alpha-blockers, other hypotensive agents and peripheral vasodilators, since the drug 3-(2,2,2-Trimethylhydrazinium® enhances their action.
Depending on the frequency of occurrence, the following groups of adverse reactions are distinguished by WHO: very often (>1/10)
Rarely-allergic reactions (redness, rashes, itching, swelling), as well as dyspeptic phenomena, tachycardia, decrease or increase in blood pressure, excitement.
Very rarely — eosinophilia, general weakness.
complex treatment of coronary heart disease (angina pectoris, myocardial infarction)
chronic heart failure and cardiomyopathy against a background of dysgormonal disorders
complex treatment of acute and chronic disorders of the blood supply to the brain (stroke and cerebrovascular insufficiency)
hemophthalmia and retinal hemorrhage of different etiology, thrombosis of the central vein of the retina and its branches, retinopathy of different etiology (diabetic, hypertonic)
reduced efficiency
mental and physical overload (including in athletes) (the drug can give a positive result during doping control (see " Special Instructions»)
withdrawal syndrome in chronic alcoholism (in combination with specific therapy of alcoholism).
complex treatment of coronary heart disease (angina pectoris, myocardial infarction)
chronic heart failure and cardiomyopathy against a background of dysgormonal disorders
complex treatment of acute and chronic disorders of the blood supply to the brain (stroke and cerebrovascular insufficiency)
hemophthalmia and retinal hemorrhage of different etiology, thrombosis of the central vein of the retina and its branches, retinopathy of different etiology (diabetic, hypertonic)
reduced efficiency
mental and physical overload (including in athletes) (the drug can give a positive result during doping control (see " Special Instructions»)
withdrawal syndrome in chronic alcoholism (in combination with specific therapy of alcoholism).
Meldonium (mildronate®) - a structural analogue of gamma-butyrobetaine-a substance that is found in every cell of the human body.
Under high load conditions, MILDRONATE® restores the balance between Delivery and oxygen demand of cells, eliminates the accumulation of toxic metabolic products in cells and protects them from damage
Due to these properties, the drug MILDRONATE® is used for the treatment of various disorders of CCC activity, blood supply to the brain, as well as to increase physical and mental performance. Due to the decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is strongly synthesized. In case of acute ischemic damage to the myocardium, the drug MILDRONATE ® slows the formation of the necrotic zone, shortens the rehabilitation period. When heart failure increases myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, the drug MILDRONATE ® improves blood circulation in the focus of ischemia, promotes the redistribution of blood in favor of the ischemic zone. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism in withdrawal syndrome
Meldonium(preparation 3-(2,2,2 — Trimethylhydrazinium®)-structural analogue of gamma-butyrobetaine-a substance that is found in every cell of the human body.
Under conditions of high load, 3-(2,2,2-Trimethylhydrazinium® restores the balance between the Delivery and oxygen demand of cells, eliminates the accumulation of toxic metabolic products in cells, protecting them from damage
Thanks to these properties, the drug 3-(2,2,2-Trimethylhydrazinium® is used for the treatment of various disorders of CCC activity, blood supply to the brain, as well as to increase physical and mental performance. Due to the decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is strongly synthesized. In case of acute ischemic damage to the myocardium, the drug 3-(2,2,2-Trimethylhydrazinium® slows the formation of the necrotic zone, shortens the rehabilitation period. When heart failure increases myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation, the drug 3-(2,2,2-Trimethylhydrazinium® improves blood circulation in the focus of ischemia, promotes the redistribution of blood in favor of the ischemic site. The drug eliminates functional disorders of the nervous system in patients with chronic alcoholism in withdrawal syndrome
The bioavailability of the drug after intravenous administration is equal to 100%. Cmax in blood plasma is achieved immediately after its administration.
Metabolized in the body with the formation of 2 main metabolites, which are excreted by the kidneys. T1 / 2 is 3-6 hours.
3-(2,2,2-Trimethylhydrazinium
Meldonium
V / m, V / V and parabulbarno. Due to the possible development of the exciting effect, it is recommended to use in the morning.
The method of administration, dose and duration of treatment are set individually, depending on the indications and severity of the disease.
Cardiovascular diseases
As part of complex therapy:
- IHD - myocardial infarction) - in / in jet 0.5-1 g per day (5-10 ml of mildronate®)
- Coronary artery disease (stable angina®) or / m 0.5 g 1-2 times a day, the course of treatment — 10-14 days, followed by a transition to ingestion. The general course of treatment is 4-6 weeks.
Stroke
As part of complex therapy in the acute phase of 0.5 g (5 ml of mildronate®) 1 ounce a day intravenously for 10 days, switching to ingestion of 0.5–1 G.the general course of treatment is 4-6 weeks.
In chronic cerebral circulatory failure - dyscirculatory encephalopathy) - 0.5 g (5 ml OF mildronate®)/m or/1 time per day for 10 days, then 0.5 g inside. The general course of treatment is 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consulting a doctor.
Ophthalmopathology (hemophthalmia and retinal hemorrhage of different etiology, thrombosis of the central vein of the retina and its branches, retinopathy of different etiology (diabetic, hypertonic)
0.05 g (0.5 ml mildronate®) is parabulbic for 10 days. Incl. is used as part of a combination therapy.
Mental and physical overload
0.5 g (5 ml mildronate®) in / m or / 1 time per day. The course of treatment-10-14 days. If necessary, the treatment is repeated after 2-3 weeks.
Chronic alcoholism
0.5 g (5 ml mildronate®) in / m or / 2 times a day. The course of treatment - 7-10 days.
V / m, V / V and parabulbarno. Due to the possible development of the exciting effect, it is recommended to use in the morning.
The method of administration, dose and duration of treatment are set individually, depending on the indications and severity of the disease.
Cardiovascular diseases
As part of complex therapy:
- CHD(myocardial infarction) - in / in jet 0.5-1 g per day(5-10 ml of the drug 3-(2,2,2-Trimethylhydrazinium®)
- Coronary artery disease (stable angina®) or / m 0.5 g 1-2 times a day, the course of treatment — 10-14 days, followed by a transition to ingestion. The general course of treatment is 4-6 weeks.
Stroke
As part of complex therapy in the acute phase of 0.5 g (5 ml of the drug 3-(2,2,2-Trimethylhydrazinium®) 1 ounce a day for 10 days, switching to ingestion of 0.5–1 G.the general course of treatment is 4-6 weeks.
In chronic cerebral circulatory failure-dyscirculatory encephalopathy) -0.5 g (5 ml of 3-(2,2,2-Trimethylhydrazinium®) / m or / 1 time per day for 10 days, then 0.5 g inside. The general course of treatment is 4-6 weeks. Repeated courses (usually 2-3 times a year) are possible after consulting a doctor.
Ophthalmopathology (hemophthalmia and retinal hemorrhage of different etiology, thrombosis of the central vein of the retina and its branches, retinopathy of different etiology (diabetic, hypertonic)
On 0.05 g (0.5 ml of the drug 3 - (2,2,2-Trimethylhydrazinium®) parabulbarno for 10 days. Incl. is used as part of a combination therapy.
Mental and physical overload
According to 0.5 g(5 ml of the drug 3-(2,2,2-Trimethylhydrazinium®) in/m or/1 time per day. The course of treatment-10-14 days. If necessary, the treatment is repeated after 2-3 weeks.
Chronic alcoholism
According to 0.5 g(5 ml of the drug 3-(2,2,2-Trimethylhydrazinium®) in/m or/2 times a day. The course of treatment - 7-10 days.
